Press coverage about Signal Genetics (NASDAQ:MGEN) has trended positive on Sunday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Signal Genetics earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.4959262214597 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
MGEN has been the topic of a number of research reports. ValuEngine raised shares of Signal Genetics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Zacks Investment Research raised shares of Signal Genetics from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Cowen and Company initiated coverage on shares of Signal Genetics in a report on Thursday, June 1st. They issued an “outperform” rating on the stock. Wedbush reissued an “outperform” rating and issued a $19.00 price objective on shares of Signal Genetics in a report on Tuesday, May 2nd. Finally, Chardan Capital reissued a “buy” rating and issued a $26.00 price objective on shares of Signal Genetics in a report on Tuesday, July 25th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $15.67.
Shares of Signal Genetics (MGEN) traded up 1.35% during trading on Friday, reaching $13.53. 22,413 shares of the company’s stock traded hands. The company has a 50 day moving average price of $12.52 and a 200-day moving average price of $12.01. Signal Genetics has a one year low of $1.80 and a one year high of $18.00. The stock’s market cap is $289.64 million.
Signal Genetics (NASDAQ:MGEN) last issued its quarterly earnings results on Wednesday, May 10th. The medical research company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.36. Signal Genetics had a negative return on equity of 109.13% and a negative net margin of 555.68%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $1 million. On average, equities research analysts expect that Signal Genetics will post ($1.72) EPS for the current fiscal year.
WARNING: “Signal Genetics (MGEN) Given Daily News Impact Rating of 0.31” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/08/06/signal-genetics-mgen-given-coverage-optimism-score-of-0-31-updated-updated.html.
About Signal Genetics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
